We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease – Neurology Module
James Galvin, MD, MPH, FANA
Jon Toledo, MD, PhD
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Closing Module
Gloria Chiang, MD
Christopher Carpenter, MD, MSC, FACEP, FAAEM, AGSF
Charles P. Vega, MD
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Emergency Medicine Module
Audience Q&A
W. Brian Gibler, MD, FACEP, FACC, FAHA
Natalie Kreitzer, MD, MS
Adrian R. Parry-Jones, FRCP, PhD
David Seiffge, MD
Real World Data and the Management of Intracranial Hemorrhages (ICH) in Anticoagulated Patients
Repletion Management for Vitamin K Antagonist Anticoagulation
Specific Reversal Therapy for Factor Xa and Factor IIa Inhibitor-Associated ICH Life-Threatening Bleeding
Reinforcement of Principles, Overcoming Treatment Barriers, and Improving Time to Treatment for ICH
Repletion or Reversal? Optimizing Specific Therapy for Direct Oral Anticoagulant (DOAC)-Related Life-Threatening Bleeding Using Real-World Experience
Development of a Care Pathway Using Specific Reversal Agents for Anticoagulated Patients With ICH
Reversal of Factor Xa Inhibitor ICH: ANNEXA-4, ANNEXA-I and Real-World Evidence
Case Presentation: Management of ICH in the Anticoagulated Patient Using Specific Reversal Therapy: Importance of Timing
Case Presentation: Management of a Patient With Vitamin K Antagonist-Associated Intracranial Hemorrhage (ICH)
Case Presentation: Management of a Patient With Factor Xa-Associated ICH Using Specific Reversal Therapy
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Reverb
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education